OXFENCARE ORAL SUSPENSION
Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
Produktens egenskaper
(SPC)
29-05-2024
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
OXFENDAZOLE
Tillgänglig från:
Ancare Ireland Ltd.
ATC-kod:
QP52AC02
INN (International namn):
OXFENDAZOLE
Dos:
22.65 Mg/Ml
Läkemedelsform:
Oral Suspension
Receptbelagda typ:
LM-Licensed Merchant
Terapeutisk grupp:
Bovine, Ovine
Terapiområde:
Oxfendazole
Terapeutiska indikationer:
Endoparasiticide
Bemyndigande status:
Authorised
Tillstånd datum:
1992-06-09
Produktens egenskaper
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Oxfencare Oral Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension.
Aqueous off white free flowing suspension
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of sensitive mature and immature gastrointestinal roundworms, lungworms and tapeworms in cattle and
sheep, including:
Gastro
-intestinal roundworms:
_Ostertagia _spp.
_Haemonchus _spp.
_Trichostrongylus _spp.
_Nematodirus _spp_., _including _N. battus_
_Cooperia _spp.
_Capillaria _spp.
_Oesophagostomum _spp.
_Chabertia _spp.
_Trichuris _spp.
Lungworms:
_Dictyocaulus _spp.
Tapeworms:
_Monezia _spp.
Each ml contains:
Active substance
Oxfendazole
22.65 mg
Excipients
Formaldehyde Solution 2.0
mg
Potassium sorbate
1.0
mg
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 29/07/2014_
_CRN 7014155_
_page number: 1_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active ingredient.
Do not use in sheep producing milk for human consumption.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could
ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of
calibration of the dosing device.
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests
Läs hela dokumentet
